Carr, Rotonya M.
Patel, Arpan
Bownik, Hillary
Oranu, Amanke
Kerner, Caroline
Praestgaard, Amy
Forde, Kimberly A.
Reddy, K. Rajender
Lichtenstein, Gary R.
Funding for this research was provided by:
National Institute on Alcohol Abuse and Alcoholism (K08-AA021424)
National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK019525, P30-DK050306, K23 DK090209, T32 DK007066)
Robert Wood Johnson Foundation (7158)
Article History
Received: 26 October 2016
Accepted: 7 February 2017
First Online: 6 March 2017
Compliance with ethical standards
:
: Dr. Gary R. Lichtenstein serves as consultant and/or participates in research for the following: Abbott Corporation, Abbvie, Actavis, Alaven, Celgene, Hospira, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals, Valeant, Santarus, Receptos, Celgene, Shire Pharmaceuticals, Takeda, and UCB. Dr. Rotonya Carr is a sub-investigator on a research study sponsored by Intercept Pharmaceuticals.